Amgen (AMGN) PT Raised to $193 at Cowen Post Q2

Go back to Amgen (AMGN) PT Raised to $193 at Cowen Post Q2

Piper Jaffray Raises Price Target on Amgen (AMGN) to $200 Following 2Q EPS Beat

July 31, 2015 10:47 AM EDT

Piper Jaffray reiterated an Overweight rating on Amgen (NASDAQ: AMGN), and raised the price target to $200.00 (from $192.00), following 2Q earnings results. Total revenue of $5.37B was ahead of consensus by $64M. EPS of $2.57 beat estimates by $0.16 aided by lower than expected R&D.... More

Amgen (AMGN) Tops Q2 EPS by 14c, Raises FY Guidance

July 30, 2015 4:05 PM EDT

Amgen (NASDAQ: AMGN) reported Q2 EPS of $2.57, $0.14 better than the analyst estimate of $2.43. Revenue for the quarter came in at $5.37 billion versus the consensus estimate of $5.32 billion.

Second Quarter 2015 Product Sales Performance

Total product sales increased 6 percent for the second quarter of 2015 versus the second quarter of 2014. The increase was driven primarily by ENBREL, Prolia, Sensipar, Kyprolis and XGEVA. Growth for the... More